Findings

What do systematic reviews say?

2,191 questions · 2,354 findings · 362 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 323 · 13.7%GRADE not reported 382 · 16.2%Very low 555 · 23.6%Low 597 · 25.4%Moderate 345 · 14.7%High 152 · 6.5%

Intervention not reported

Pitavastatin dose · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Pitavastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Pitavastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 777 participants
High

Intervention not reported

mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Pitavastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
32 studies · 2789 participants
High

BoNT‐A vs usual care or physiotherapy

Instrumented gait analysis (kinematics) (not measured) · children with CP

The review found no eligible studies for this question.

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs usual care or physiotherapy

Function · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 191 participants
Very low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 199 participants
Very low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low

BoNT‐A vs usual care or physiotherapy

Range of motion (passive ankle dorsiflexion) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 272 participants
Very low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 250 participants
Very low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Very low

BoNT‐A vs usual care or physiotherapy

Satisfaction (not measured) · children with CP

The review found no eligible studies for this question.

2 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs usual care or physiotherapy

Spasticity (ankle plantarflexors) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 226 participants
Very low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 258 participants
Very low
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Very low

BoNT‐A vs usual care or physiotherapy

Adverse events · children with CP

The review found no eligible studies for this question.

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 206 participants
Very low

BoNT‐A vs usual care or physiotherapy

Gait assessment ‐ not measured · children with CP

The review found no eligible studies for this question.

2 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs usual care or physiotherapy

Satisfaction · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

BoNT‐A vs sham

Instrumented gait analysis (peak ankle dorsiflexion in stance) · children with CP

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Moderate

BoNT‐A vs sham

Observational gait analysis (improvement) · children with CP

BoNT‐A probably leads to higher observational gait analysis (improvement) compared with placebo or sham (moderate certainty).

2 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
RR 1.66 [1.16, 2.37]
4 studies · 261 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
RR 1.9 [1.32, 2.74]
3 studies · 248 participants
Moderate

BoNT‐A vs sham

Function · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 305 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 327 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 91 participants
Moderate

BoNT‐A vs sham

Range of motion (passive ankle dorsiflexion) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 291 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 150 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

BoNT‐A vs sham

Satisfaction · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 74 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Moderate

BoNT‐A vs sham

Spasticity (ankle plantarflexors) · children with CP

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 156 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 144 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Moderate

BoNT‐A vs sham

Adverse events · children with CP

BoNT‐A showed no clear difference in adverse events compared with placebo or sham (moderate certainty).

3 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
RR 1.29 [0.87, 1.93]
12 studies · 918 participants
Moderate
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs sham

Instrumented gait analysis (kinematics) (not measured) · children with CP

The review found no eligible studies for this question.

2 findings from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BoNT‐A vs sham

Gait assessment ‐ not measured · children with CP

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found